August, 2025
PETAL Consortium receives grant from Acrotech Biopharma Inc.
PETAL Consortium is pleased to announce it has received an educational grant from Acrotech Biopharma Inc.—a global pharmaceutical company dedicated to developing innovative medications—to support the creation of PETAL’s patient education portal.
PETAL Consortium receives grant from Acrotech Biopharma Inc.
PETAL Consortium is pleased to announce it has received an educational grant from Acrotech Biopharma Inc.—a global pharmaceutical company dedicated to developing innovative medications—to support the creation of PETAL’s patient education portal.
In this Q&A, meet Ijeoma Eche-Ugwu, PETAL Consortium’s Co-investigator in Quality of Life Measures!
Ijeoma Julie Eche-Ugwu, PhD, MPH, FNP-BC, AOCNP, CPHON, BMTCN is a Nurse Scientist at the Phyllis F. Cantor Center for Research in Nursing and Patient Care Services at Dana-Farber Cancer Institute and an Instructor in Medicine at Harvard Medical School. She also serves as the Associate Director of the Pediatrics and Family Health Core within the Cantor Center’s Precision Health Symptom Science Program.
In this Q&A, meet Ijeoma Eche-Ugwu, PETAL Consortium’s Co-investigator in Quality of Life Measures!
Ijeoma Julie Eche-Ugwu, PhD, MPH, FNP-BC, AOCNP, CPHON, BMTCN is a Nurse Scientist at the Phyllis F. Cantor Center for Research in Nursing and Patient Care Services at Dana-Farber Cancer Institute and an Instructor in Medicine at Harvard Medical School. She also serves as the Associate Director of the Pediatrics and Family Health Core within the Cantor Center’s Precision Health Symptom Science Program.
July, 2025
In this Q&A, meet Emma DeMarco, PETAL Consortium’s Clinical Research Coordinator!
Emma DeMarco is a Clinical Research Coordinator at Massachusetts General Hospital. She earned her bachelor's degree in Bioengineering at Northeastern University. As an undergraduate student, she has worked as a Student Researcher at Harvard Medical School and a Research Intern at NextPoint Therapeutics.
In this Q&A, meet Emma DeMarco, PETAL Consortium’s Clinical Research Coordinator!
Emma DeMarco is a Clinical Research Coordinator at Massachusetts General Hospital. She earned her bachelor's degree in Bioengineering at Northeastern University. As an undergraduate student, she has worked as a Student Researcher at Harvard Medical School and a Research Intern at NextPoint Therapeutics.
Dr. Salvia Jain interviewed by Becker's Healthcare
Salvia Jain, MD, principal investigator and founder of PETAL Consortium, spoke with Becker's Healthcare about how combining the drugs duvelisib and romidepsin may offer a promising path to stem cell transplant for patients with peripheral and cutaneous T-cell lymphomas.
Dr. Salvia Jain interviewed by Becker's Healthcare
Salvia Jain, MD, principal investigator and founder of PETAL Consortium, spoke with Becker's Healthcare about how combining the drugs duvelisib and romidepsin may offer a promising path to stem cell transplant for patients with peripheral and cutaneous T-cell lymphomas.
In this Q&A, meet Caroline MacVicar, former Clinical Research Coordinator for PETAL Consortium.
Caroline is an incoming first year medical student in the Army at Uniformed Services University. She earned her bachelor's degree in Biological Sciences from Wellesley College. She was a volunteer at the Newton-Wellesley Hospital and was an undergraduate research assistant in a microbiology lab at Wellesley. We'll miss you Caroline!
In this Q&A, meet Caroline MacVicar, former Clinical Research Coordinator for PETAL Consortium.
Caroline is an incoming first year medical student in the Army at Uniformed Services University. She earned her bachelor's degree in Biological Sciences from Wellesley College. She was a volunteer at the Newton-Wellesley Hospital and was an undergraduate research assistant in a microbiology lab at Wellesley. We'll miss you Caroline!
In this Q&A, meet Mark Sorial, PETAL Consortium’s Investigator and Biostatistician!
Mark Sorial is an Investigator and Biostatistician at Massachusetts General Hospital. He earned his Doctor of Pharmacy degree at the Massachusetts College of Pharmacy and Health Sciences and is now completing his Masters of Public Health at the University of Massachusetts Amherst. He is currently a Clinical Pharmacist Specialist at the Dana-Farber Cancer Institute.
PETAL Research Featured in Mass General Brigham News
In this research spotlight, learn about Mark Sorial's recent publication on improved survival for patients with lymphoma with the use of existing drug therapies. He shares how these discoveries can improve patient care and lead to better treatment strategies.
Research Spotlight: Global Study Finds Improved Survival for Aggressive Blood Cancer with Early Use of Existing Drug Therapies
In this research spotlight, learn about Mark Sorial's recent publication on improved survival for patients with lymphoma with the use of existing drug therapies. He shares how these discoveries can improve patient care and lead to better treatment strategies.
In this Q&A, meet Mark Sorial, PETAL Consortium’s Investigator and Biostatistician!
Mark Sorial is an Investigator and Biostatistician at Massachusetts General Hospital. He earned his Doctor of Pharmacy degree at the Massachusetts College of Pharmacy and Health Sciences and is now completing his Masters of Public Health at the University of Massachusetts Amherst. He is currently a Clinical Pharmacist Specialist at the Dana-Farber Cancer Institute.
PETAL enrolls its 100th patient!
We're excited to share that PETAL Consortium has officially reached 100 participants across all activated sites! This is a significant and inspiring milestone that reflects the dedication, coordination, and hard work our team continues to bring. Let's take a moment to celebrate this achievement and reach even more patients in need!
PETAL enrolls its 100th patient!
We're excited to share that PETAL Consortium has officially reached 100 participants across all activated sites! This is a significant and inspiring milestone that reflects the dedication, coordination, and hard work our team continues to bring. Let's take a moment to celebrate this achievement and reach even more patients in need!
Research Spotlight: A new calculator to make personalized decisions for patients with T-cell and natural killer-cell lymphomas
In this research spotlight, learn about Jessy Xinyi Han’s recent publication on a new risk scoring system that takes patient information and helps doctors better predict which patients will do well or poorly after their cancer comes back or does not respond to initial treatment. She shares how the team's findings could provide doctors with a new, easy-to-use tool to better predict patient outcomes and personalize treatment for T-cell lymphoma.
Research Spotlight: A new calculator to make personalized decisions for patients with T-cell and natural killer-cell lymphomas
In this research spotlight, learn about Jessy Xinyi Han’s recent publication on a new risk scoring system that takes patient information and helps doctors better predict which patients will do well or poorly after their cancer comes back or does not respond to initial treatment. She shares how the team's findings could provide doctors with a new, easy-to-use tool to better predict patient outcomes and personalize treatment for T-cell lymphoma.
5 Things an Oncologist Wants You to Know About T-cell Lymphoma
T-cell lymphoma is a rare and aggressive blood cancer that affects the immune system’s T cells. Discover what causes this disease and why seeing a lymphoma specialist is crucial for accurate diagnosis, personalized treatment, and better outcomes.
5 Things an Oncologist Wants You to Know About T-cell Lymphoma
T-cell lymphoma is a rare and aggressive blood cancer that affects the immune system’s T cells. Discover what causes this disease and why seeing a lymphoma specialist is crucial for accurate diagnosis, personalized treatment, and better outcomes
Regeneron Joins PETAL Consortium as a Funding Partner for Our Pathology
Initiative!
We are thrilled to announce that Regeneron Pharmaceuticals has awarded an educational grant to support PETAL Consortium’s central pathology review initiative, which leverages digital pathology to ensure the consistent and precise diagnosis of peripheral T-cell lymphoma.
Regeneron Joins PETAL Consortium as a Funding Partner for Our
Pathology Initiative!
We are thrilled to announce that Regeneron Pharmaceuticals has awarded an educational grant to support PETAL Consortium’s central pathology review initiative, which leverages digital pathology to ensure the consistent and precise diagnosis of peripheral T-cell lymphoma.
Research Spotlight: Study Demonstrates Drug Combination is Well-Tolerated, Safe and Effective for Patients with Aggressive Blood Cancer
In this research spotlight, learn about Josie Ford’s recent publication on a novel drug combination for lymphoma. She shares how the team's findings could shape future approaches to care for patients with aggressive blood cancers.
Research Spotlight: Study Demonstrates Drug Combination is Well-Tolerated, Safe and Effective for Patients with Aggressive Blood Cancer
In this research spotlight, learn about Josie Ford’s recent publication on a novel drug combination for lymphoma. She shares how the team's findings could shape future approaches to care for patients with aggressive blood cancers.
In this Q&A, meet Alexandra Lenart, PETAL Consortium’s CRC!
Alexandra Lenart is a Clinical Research Coordinator (CRC) at Massachusetts General Hospital. She earned her bachelor’s degree in Economics at Wellesley College. Before joining PETAL Consortium, she was a Scrub Technician at Oral and Maxillofacial Surgery of Central New Jersey, as well as a Research Assistant in the Tetel Lab at Wellesley College.
In this Q&A, meet Alexandra Lenart, PETAL Consortium’s CRC!
Alexandra Lenart is a Clinical Research Coordinator (CRC) at Massachusetts General Hospital. She earned her bachelor’s degree in Economics at Wellesley College. Before joining PETAL Consortium, she was a Scrub Technician at Oral and Maxillofacial Surgery of Central New Jersey, as well as a Research Assistant in the Tetel Lab at Wellesley College.
Josie Ford was interviewed by Blood Cancers Today!
We're excited to share that Josie Ford was interviewed by Blood Cancers Today about her recently published study in Blood Advances, which investigates the efficacy of the drug combination duvelisib and romidepsin in patients with rare and aggressive blood cancers.
Josie Ford was interviewed by Blood Cancers Today!
We're excited to share that Josie Ford was interviewed by Blood Cancers Today about her recently published study in Blood Advances, which investigates the efficacy of the drug combination duvelisib and romidepsin in patients with rare and aggressive blood cancers.
Real-World Data Study Led by Dr. Salvia Jain Highlights Promising Treatment for Aggressive Blood Cancer
A new study led by PETAL investigator Dr. Salvia Jain demonstrates that a combination of two blood cancer medications is well tolerated, safe, and effective for patients with aggressive blood cancers who do not respond to standard therapy. The research, based on real-world data, is now featured in the Mass General Brigham Newsroom.
Real-World Data Study Led by Dr. Salvia Jain Highlights Promising Treatment for Aggressive Blood Cancer
A new study led by PETAL investigator Dr. Salvia Jain demonstrates that a combination of two blood cancer medications is well tolerated, safe, and effective for patients with aggressive blood cancers who do not respond to standard therapy. The research, based on real-world data, is now featured in the Mass General Brigham Newsroom.
June, 2025
Founder and Principal investigator of the PETAL Consortium
In this Q&A, meet Dr. Salvia Jain–founder and principal investigator of PETAL Consortium–as she shares how her journey in medicine began and what inspired her to focus on blood cancer research.
Founder and Principal investigator of the PETAL Consortium
In this Q&A, meet Dr. Salvia Jain–founder and principal investigator of PETAL Consortium–as she shares how her journey in medicine began and what inspired her to focus on blood cancer research.
May, 2025
PETAL Consortium Featured in ASCO Post!
We are excited to share that PETAL Consortium is featured in the ASCO Post! The article highlights our groundbreaking study, which reveals how a specific sequence of therapies can significantly improve survival rates for patients with relapsed/refractory T- and NK-cell lymphomas. By leveraging global data from PETAL, we are moving closer to refining treatment strategies and providing new hope for patients with limited treatment options.
PETAL Consortium Featured in ASCO Post!
We are excited to share that PETAL Consortium is featured in the ASCO Post! The article highlights our groundbreaking study, which reveals how a specific sequence of therapies can significantly improve survival rates for patients with relapsed/refractory T- and NK-cell lymphomas. By leveraging global data from PETAL, we are moving closer to refining treatment strategies and providing new hope for patients with limited treatment options.
PETAL Research Featured in Mass General Brigham News
Our recent publication in the British Journal of Haematology has been featured by Mass General Brigham. The news release underscores the PETAL Consortium’s innovative and impactful research in guiding personalized treatment strategies for relapsed and refractory T- and NK-cell lymphomas.
PETAL Research Featured in Mass General Brigham News
Our recent publication in the British Journal of Haematology has been featured by Mass General Brigham. The news release underscores the PETAL Consortium’s innovative and impactful research in guiding personalized treatment strategies for relapsed and refractory T- and NK-cell lymphomas.
Read the press release
Forecasting Optimal Treatments in Relapsed/Refractory Mature T- and NK-Cell Lymphomas – The PETAL Consortium’s latest paper published in the British Journal of Haematology.
Forecasting Optimal Treatments in Relapsed/Refractory Mature T- and NK-Cell Lymphomas – The PETAL Consortium’s latest paper published in the British Journal of Haematology.
We are thrilled that our clinical researcher Caroline MacVicar has been accepted to and plans on attending medical school at Uniformed Services University (USU). Congratulations!
We are thrilled that our clinical researcher Caroline MacVicar has been accepted to and plans on attending medical school at Uniformed Services University (USU). Congratulations!
We are delighted to congratulate Dhruv Mistry, a key PETAL team member, on earning his M.B.B.S. degree. We cannot wait to see his career unfold.
We are delighted to congratulate Dhruv Mistry, a key PETAL team member, on earning his M.B.B.S. degree. We cannot wait to see his career unfold.
April, 2025
Blood Cancers Today spoke with the PETAL sub-investigator, Mark Sorial, on “What Is the Optimal Treatment Sequence for Relapsed or Refractory T-Cell Lymphoma?”
Blood Cancers Today spoke with the PETAL sub-investigator, Mark Sorial, on “What Is the Optimal Treatment Sequence for Relapsed or Refractory T-Cell Lymphoma?”
We are thrilled to share that Emmanuel Nwodo has been awarded a prestigious Career Exploration and Development (CXD) grant from Bowdoin College for a 10-week internship with the PETAL Consortium. This grant will support his hands-on research experience with PETAL and culminate in a poster presentation, helping to advance his career in research and data science. Congratulations, Emmanuel!
We are thrilled to share that Emmanuel Nwodo has been awarded a prestigious Career Exploration and Development (CXD) grant from Bowdoin College for a 10-week internship with the PETAL Consortium. This grant will support his hands-on research experience with PETAL and culminate in a poster presentation, helping to advance his career in research and data science. Congratulations, Emmanuel!
March, 2025
We are excited to share that our latest manuscript Forecasting optimal treatments in relapsed/refractory mature T- and NK-cell lymphomas: a global PETAL Consortium study manuscript has been accepted for publication in the British Journal of Haematology.
We are excited to share that our latest manuscript Forecasting optimal treatments in relapsed/refractory mature T- and NK-cell lymphomas: a global PETAL Consortium study manuscript has been accepted for publication in the British Journal of Haematology.
February, 2025
Our paper Global outcomes and prognosis for relapsed/refractory
mature T-cell and NK-cell lymphomas: results from the PETAL consortium
gets highlighted on Blood Advances Today.
We are excited to share this editorial on our Blood Advances
paper PETAL: a global view on R/R T/NK-lymphoma
treatment reality.
MGH the founding site will be participating in the phase III trial of Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma.
MGH the founding site will be participating in the phase III trial of Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma.
An inspiring story shared by our PETAL patient on how Specialized Expertise Transformed a Critical Setback From Peripheral T-cell Lymphoma Into Hope
An inspiring story shared by our PETAL patient on how Specialized Expertise Transformed a Critical Setback From Peripheral T-cell Lymphoma Into Hope
January, 2025
Blood Cancers Today spoke with researchers from the Salvia Jain Lab to learn more about the goals and initiatives of the PETAL Consortium. Leora Boussi, MD, Angela Koh, and Jessy Xinyi Han discuss their study of a novel scoring system using one of the largest international global cohorts of 925 patients with relapsed or refractory mature T-cell and NK-cell lymphomas.
Blood Cancers Today spoke with researchers from the Salvia Jain Lab to learn more about the goals and initiatives of the PETAL Consortium. Leora Boussi, MD, Angela Koh, and Jessy Xinyi Han discuss their study of a novel scoring system using one of the largest international global cohorts of 925 patients with relapsed or refractory mature T-cell and NK-cell lymphomas.
PETAL has been prominently featured in the MGH Cancer Center Curtain Raiser and the Mass General Brigham Cancer Center newsletter, which reaches over 20,000 individuals across academia, industry, and other fields. We are excited to share key updates on our research with this wide audience.
PETAL has been prominently featured in the MGH Cancer Center Curtain Raiser and the Mass General Brigham Cancer Center newsletter, which reaches over 20,000 individuals across academia, industry, and other fields. We are excited to share key updates on our research with this wide audience.
We are pleased to share that the University of Pennsylvania (UPenn) is our third participating site which is now active for enrollment
We are pleased to share that the University of Pennsylvania (UPenn) is our third participating site which is now active for enrollment
PETAL goes LIVE on social media! As we ramp up our efforts, the PETAL Consortium is now active on Facebook, LinkedIn, Instagram, and Twitter. Follow us for regular updates, insightful resources, and exciting developments in T-cell lymphoma research. Let’s make science accessible and drive meaningful change together.
PETAL goes LIVE on social media! As we ramp up our efforts, the PETAL Consortium is now active on Facebook, LinkedIn, Instagram, and Twitter. Follow us for regular updates, insightful resources, and exciting developments in T-cell lymphoma research. Let’s make science accessible and drive meaningful change together.
December, 2024
The PETAL team proudly participated in the ASH 2024 conference, showcasing our work through three poster presentations and an oral session. This opportunity highlighted PETAL’s innovative contributions to the field of hematology.
The PETAL team proudly participated in the ASH 2024 conference, showcasing our work through three poster presentations and an oral session. This opportunity highlighted PETAL’s innovative contributions to the field of hematology.
The PETAL Consortium held its second annual Investigators’ Meeting, highlighting significant study progress, sharing operational and regulatory updates, along with celebrating milestones, and outlining strategic goals for the future of the consortium.
The PETAL Consortium held its second annual Investigators’ Meeting, highlighting significant study progress, sharing operational and regulatory updates, along with celebrating milestones, and outlining strategic goals for the future of the consortium.
September, 2024
Mass General Cancer Center organized a 5k Run-Walk where the PETAL team along with the whole Cancer Center was running for a cause. Where we raised awareness and funds to support our research with the help, support and dedication of our patients, families and friends who joined us for a cause.
Mass General Cancer Center organized a 5k Run-Walk where the PETAL team along with the whole Cancer Center was running for a cause. Where we raised awareness and funds to support our research with the help, support and dedication of our patients, families and friends who joined us for a cause.
PETAL consortium’s second site Dana Farber Cancer Institute (DFCI) is successfully activated for enrollment
PETAL consortium’s second site Dana Farber Cancer Institute (DFCI) is successfully activated for enrollment
Congratulations to Shambhavi Singh, MD, PhD, for being selected as a recipient of the 2024 ASH Hematology Opportunities for the Next-Generation of Research Scientists (HONORS) Award.
Shambhavi Singh
Acrotech Biopharma joins PETAL, supporting the development of the consortium and personalized treatments for rare lymphomas.
Acrotech Biopharma joins PETAL, supporting the development of the consortium and personalized treatments for rare lymphomas.
June, 2024
PETAL Consortium @TCLF 2024 excited to share our work through many oral and poster presentations
PETAL Consortium @TCLF 2024 excited to share our work through many oral and poster presentations
Newsroom
Newsroom
@2025 PETAL Consortium • All rights reserved
@2025 PETAL Consortium • All rights reserved